Prelude Capital Management’s BioAtla BCAB Stock Holding History

Prelude Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-608	Closed	-$53.5K	–	1224
2024 Q3	$53.5K	Buy	+608	New	+$51K	﹤0.01%	1213
2023 Q4	–	Sell	-222	Closed	-$18.8K	–	1136
2023 Q3	$18.8K	Sell	222 -98	-31%	-$12.5K	﹤0.01%	1072
2023 Q2	$48K	Buy	320 +63	+25%	+$10.8K	﹤0.01%	974
2023 Q1	$34.4K	Sell	257 -66	-20%	-$11.9K	﹤0.01%	1027
2022 Q4	$133K	Buy	+323	New	+$134K	0.01%	1029
2022 Q3	–	Sell	-316	Closed	-$45K	–	1583
2022 Q2	$45K	Buy	+316	New	+$50.3K	﹤0.01%	1490

Other funds holding BCAB

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's BCAB Position: Q4 2024 in Review

Prelude Capital Management sold out of BioAtla (BCAB) in Q4 2024, closing a stake of 608 shares — an estimated $53.5K sold.

Prelude Capital Management first reported a position in BCAB in Q2 2022 and held it in 6 quarters. The position peaked at $133K in Q4 2022. 67 funds tracked by Wall St. Rank hold BCAB as of Q4 2024.

Prelude Capital Management reported no remaining BioAtla position as of Q4 2024 after selling out during the quarter.
Prelude Capital Management sold 608 BioAtla shares in Q4 2024, an estimated $53.5K.
Prelude Capital Management first reported a position in BioAtla in Q2 2022 and held it in 6 quarters.
Prelude Capital Management's BioAtla position peaked at $133K in Q4 2022.
67 funds tracked by Wall St. Rank held BioAtla as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.